Cargando…

A Pilot Study of the Short Term Effectiveness and Safety of Amniotic Fluid in Severe Dry Eye Disease

The aim of this study was to evaluate if amniotic fluid (AF) mixed with artificial tears or soaked with a soft contact lens (SCL) as a treatment for severe dry eye disease (DED) would improve its signs or symptoms. In this retrospective pilot study 22 consecutive eyes of 11 patients with level 3 DED...

Descripción completa

Detalles Bibliográficos
Autores principales: CHEN, Ming, CHANG, Chao Kai, LIN, Szu Yuan, CHEN, Mindy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medical Hypothesis, Discovery & Innovation Ophthalmology 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592303/
https://www.ncbi.nlm.nih.gov/pubmed/31263717
_version_ 1783429871251226624
author CHEN, Ming
CHANG, Chao Kai
LIN, Szu Yuan
CHEN, Mindy
author_facet CHEN, Ming
CHANG, Chao Kai
LIN, Szu Yuan
CHEN, Mindy
author_sort CHEN, Ming
collection PubMed
description The aim of this study was to evaluate if amniotic fluid (AF) mixed with artificial tears or soaked with a soft contact lens (SCL) as a treatment for severe dry eye disease (DED) would improve its signs or symptoms. In this retrospective pilot study 22 consecutive eyes of 11 patients with level 3 DED classified by DEWS 1 (Dry Eye WorkShop 1 2007), were included in the study between June 1 and September 30 in 2017. The study was conducted before DEWS II (Dry Eye WorkShop II 2017), which was published in October 2017. Therefore, DEWS II was not adopted for this study. Soft Contact Lens Acuvue Oasys of Plano with 8.8 base curve and 14 mm diameters by Johnson and Johnson were used to soak in FloGraft, which is an AF, for 30 minutes before placing in 12 eyes in Group 1. The contact lenses were placed in the left eye for 1 week. In Group 2, 10 eyes used 6 mL of artificial tears mixed with 0.25 mL of AF, which were applied to the eye four times a day for 1 week. No other eye medications were used. The eyes that were included had diffuse punctate staining and fast tear breaking times of <5 seconds with severe ocular symptoms (DEWS 1 level 3-4). Photos of fluorescein stain corneas before the treatment and 1 week after the treatment were used to compare the distribution of punctate staining as the objective outcomes for signs. Several questions adopted from the Ocular Surface disease Index (OSDI) about subjective symptoms before and after the treatment were asked, and documented on the chart. Improvement either in symptoms or signs or both of DED after 1 week at follow-up examination was recorded. Group 1, with SCL 46% had improvement after 1 week and Group 2, with artificial tears 50% had improvement after 1 week. Improvement means either symptom relief or comparatively decreased distribution of punctate staining on the cornea or both. No cases had inflammation, infection, irritation or blurred vision. We concluded that FloGraft as an AF can safely improve the symptoms or the signs of severe DED either as a mix with artificial tears or soaked with SCL by about 50% in this case series without evidence of irritation, inflammation or blurred vision in the short term.
format Online
Article
Text
id pubmed-6592303
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Medical Hypothesis, Discovery & Innovation Ophthalmology
record_format MEDLINE/PubMed
spelling pubmed-65923032019-07-01 A Pilot Study of the Short Term Effectiveness and Safety of Amniotic Fluid in Severe Dry Eye Disease CHEN, Ming CHANG, Chao Kai LIN, Szu Yuan CHEN, Mindy Med Hypothesis Discov Innov Ophthalmol Original Article The aim of this study was to evaluate if amniotic fluid (AF) mixed with artificial tears or soaked with a soft contact lens (SCL) as a treatment for severe dry eye disease (DED) would improve its signs or symptoms. In this retrospective pilot study 22 consecutive eyes of 11 patients with level 3 DED classified by DEWS 1 (Dry Eye WorkShop 1 2007), were included in the study between June 1 and September 30 in 2017. The study was conducted before DEWS II (Dry Eye WorkShop II 2017), which was published in October 2017. Therefore, DEWS II was not adopted for this study. Soft Contact Lens Acuvue Oasys of Plano with 8.8 base curve and 14 mm diameters by Johnson and Johnson were used to soak in FloGraft, which is an AF, for 30 minutes before placing in 12 eyes in Group 1. The contact lenses were placed in the left eye for 1 week. In Group 2, 10 eyes used 6 mL of artificial tears mixed with 0.25 mL of AF, which were applied to the eye four times a day for 1 week. No other eye medications were used. The eyes that were included had diffuse punctate staining and fast tear breaking times of <5 seconds with severe ocular symptoms (DEWS 1 level 3-4). Photos of fluorescein stain corneas before the treatment and 1 week after the treatment were used to compare the distribution of punctate staining as the objective outcomes for signs. Several questions adopted from the Ocular Surface disease Index (OSDI) about subjective symptoms before and after the treatment were asked, and documented on the chart. Improvement either in symptoms or signs or both of DED after 1 week at follow-up examination was recorded. Group 1, with SCL 46% had improvement after 1 week and Group 2, with artificial tears 50% had improvement after 1 week. Improvement means either symptom relief or comparatively decreased distribution of punctate staining on the cornea or both. No cases had inflammation, infection, irritation or blurred vision. We concluded that FloGraft as an AF can safely improve the symptoms or the signs of severe DED either as a mix with artificial tears or soaked with SCL by about 50% in this case series without evidence of irritation, inflammation or blurred vision in the short term. Medical Hypothesis, Discovery & Innovation Ophthalmology 2019 /pmc/articles/PMC6592303/ /pubmed/31263717 Text en © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial 4.0 International License (http://creativecommons.org/licenses/by/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
spellingShingle Original Article
CHEN, Ming
CHANG, Chao Kai
LIN, Szu Yuan
CHEN, Mindy
A Pilot Study of the Short Term Effectiveness and Safety of Amniotic Fluid in Severe Dry Eye Disease
title A Pilot Study of the Short Term Effectiveness and Safety of Amniotic Fluid in Severe Dry Eye Disease
title_full A Pilot Study of the Short Term Effectiveness and Safety of Amniotic Fluid in Severe Dry Eye Disease
title_fullStr A Pilot Study of the Short Term Effectiveness and Safety of Amniotic Fluid in Severe Dry Eye Disease
title_full_unstemmed A Pilot Study of the Short Term Effectiveness and Safety of Amniotic Fluid in Severe Dry Eye Disease
title_short A Pilot Study of the Short Term Effectiveness and Safety of Amniotic Fluid in Severe Dry Eye Disease
title_sort pilot study of the short term effectiveness and safety of amniotic fluid in severe dry eye disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592303/
https://www.ncbi.nlm.nih.gov/pubmed/31263717
work_keys_str_mv AT chenming apilotstudyoftheshorttermeffectivenessandsafetyofamnioticfluidinseveredryeyedisease
AT changchaokai apilotstudyoftheshorttermeffectivenessandsafetyofamnioticfluidinseveredryeyedisease
AT linszuyuan apilotstudyoftheshorttermeffectivenessandsafetyofamnioticfluidinseveredryeyedisease
AT chenmindy apilotstudyoftheshorttermeffectivenessandsafetyofamnioticfluidinseveredryeyedisease
AT chenming pilotstudyoftheshorttermeffectivenessandsafetyofamnioticfluidinseveredryeyedisease
AT changchaokai pilotstudyoftheshorttermeffectivenessandsafetyofamnioticfluidinseveredryeyedisease
AT linszuyuan pilotstudyoftheshorttermeffectivenessandsafetyofamnioticfluidinseveredryeyedisease
AT chenmindy pilotstudyoftheshorttermeffectivenessandsafetyofamnioticfluidinseveredryeyedisease